Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Empresa francesa ofrece vectores derivados del virus del herpes simple tipo 1 y episomas replicativos de ADN para aplicaciones terapéuticas

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOFR20170126001
Publicado:
02/02/2017
Caducidad:
02/02/2018
Resumen:
Una empresa francesa de biotecnología especializada en nuevas tecnologías de transferencia génica basadas en virus y ADN ha desarrollado vectores derivados del virus del herpes simple tipo 1 para aplicaciones terapéuticas y no terapéuticas en los campos de vacunas, terapias génicas, terapias celulares, terapias inmuno-oncológicas y medicina regenerativa. Los vectores de transferencia génica se adaptan a cualquier tipo de célula para una expresión sostenible, específica y segura de uno o múltiples genes de células quiescentes o en división sin modificación del genoma. La empresa busca socios con el fin de establecer acuerdos de licencia o cooperación en materia de I+D.

Details

Tittle:
A French SME is offering Herpes simplex virus type 1 derived vectors and replicative DNA episomes for therapeutic applications.
Summary:
A French biotechnology company developing innovative viral based and DNA based gene transfer technologies is offering herpes simplex virus type 1 vectors for therapeutic and non therapeutic applications in the field of vaccines, gene therapies, cell therapies, immuno-onco-therapies and regenerative medicine via a licensing or an R-Y-D cooperation agreement.
Description:
The French biotech company, created in 2006, develops innovative gene transfer technologies (Herpes Simplex Virus recombinant viruses - HSV derived amplicon vectors - replicative DNA episomes) for research projects, improvement of industrial processes and for therapeutic applications.

Today´s problematics in gene transfer technologies are the cytotoxicity of the vectors (cell toxicity - DNA integration leading to cell immortalization - immunogenicity in vivo), the poor efficacy of cell transduction (esp. in primary cells), the low DNA payload (i.e. Adeno-Associated Virus AAV vectors), the low and transient gene expression and the difficulty to produce large amount of vectors at reasonable cost.

To circumvent all these problems, the French company has developed various vectors (DNA or viral based vectors) for efficient cell transduction, multiple gene transfer (combinatorial vectors) without any cytotoxicity (i.e. no DNA integration in the cell genome) and easy to produce.

Thanks to the innovative gene transfer technologies, the company has developed partnerships with public research centres, biotechs and pharmas to develop new therapeutic approaches, such as :
- a tuberculosis vaccine
- gene therapy for the treatment of refractory epilepsy
- an oncotherapy against pancreatic and gliobalstoma cancers
- a cure for labial and genital herpes infections.

The French company is now seeking other partners via a licence agreement or a research cooperation agreement, for the development of :
- combinatorial vaccines i.e. strong transient or long term regulated expression of multiple antigens and possibly immunomodulators
- immunotherapies and oncotherapies, i.e. combinatorial expression of multiple inhibitors of checkpoint inhibitors, oncolytic viruses, Chimeric Antigen Receptor CAR T-cells
- gene therapies, i.e. regulated and specific expression of multiple genes, including large genes
- cell therapies and regenerative medicine, i.e. cell reprogramming - transdifferenciation
Advantages and Innovations:
- gene transfer vectors can be adapted to any cell type to allow strong (and / or regulated), sustainable, specific and safe gene expression of one or multiple genes in quiescent or dividing cells without modification of the cell genome
- vectors have the capacity to transfer 152 kbp of DNA which is significantly higher than other commonly used viral vectors
- vectors have no cytotoxicity
- efficient cell transduction for most mammals
- can be produced at large scale

Stage of Development:
Available for demonstration
IPs:
Secret Know-how

Partner sought

Type and Role of Partner Sought:
Biotech and pharmas are sought for therapeutic development or industrial process improvement, based on the French biotech company´s gene transfer technologies. Partners will financially support the adaptation of the gene transfer technologies for their specific requirement via a license agreement or via a research cooperation agreement. The French company will provide the vectors and implement the proof of concept and the preclinical studies so that the partner can develop the therapeutic approach further to the clinical stage.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
French

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06001012 Investigaciones médicas
06001009 Terapia genética - ADN
06001006 Vacunas humanas
06001018 Virus, virología / antibióticos / bacteriología